Management of central diabetes insipidus.
Best Pract Res Clin Endocrinol Metab
; 34(5): 101385, 2020 09.
Article
em En
| MEDLINE
| ID: mdl-32169331
The treatment of central diabetes insipidus has not changed significantly in recent decades, and dDAVP and replacement of free water deficit remain the cornerstones of treatment. Oral dDAVP has replaced nasal dDAVP as a more reliable mode of treatment for chronic central diabetes insipidus. Hyponatraemia is a common side effect, occurring in one in four patients, and should be avoided by allowing a regular break from dDAVP to allow a resultant aquaresis. Hypernatraemia is less common, and typically occurs during hospitalization, when access to water is restricted, and in cases of adipsic DI. Management of adipsic DI can be challenging, and requires initial inpatient assessment to establish dose of dDAVP, daily fluid prescription, and eunatraemic weight which can guide day-to-day fluid targets in the long-term.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diabetes Insípido Neurogênico
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Endocrinol Metab
Ano de publicação:
2020
Tipo de documento:
Article